135632-53-0

Basic information

• Product Name: 4-(Boc-Aminomethyl)piperidine
• Synonyms: 4-(2-BOC-AMINOMETHYL) PIPERIDINE;4-AMINOMETHYLPIPERIDINE, BOC PROTECTED;4-(BOC-AMINOMETHYL)PIPERIDINE;4-N-BOC-AMINOMETHYL PIPERIDINE;4-(TERT-BUTYLOXYCARBONYL-AMINOMETHYL)-PIPERIDINE;4-(TERT-BUTOXYCARBONYLAMINOMETHYL)PIPERIDINE;4-(T-BUTYLOXYCARBONYL-AMINOMETHYL)-PIPERIDINE;BUTTPARK 43\57-92
• CAS NO: 135632-53-0
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: pharmacetical;Aminomethyl's;Pyrans, Piperidines &Piperazines;Piperidine;Pyrans, Piperidines & Piperazines
• Mol File: 135632-53-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 321.8 °C at 760 mmHg
• Flash Point: 148.4 °C
• Appearance: /
• Density: 0.981 g/cm³
• Vapor Pressure: 0.00029mmHg at 25°C
• Storage Temp.: Refrigerated.
• Solubility: Soluble in DMSO.
• PKA: 12.72±0.46(Predicted)
• CAS DataBase Reference: 4-(Boc-Aminomethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Boc-Aminomethyl)piperidine(135632-53-0)
• EPA Substance Registry System: 4-(Boc-Aminomethyl)piperidine(135632-53-0)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36/38
• Safety Statements: 26-36/37/39-45
• RIDADR: 3259
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 135632-53-0(Hazardous Substances Data)

Usage

Uses

4-(Boc-aminomethyl)piperidine is used as an important raw material and intermediate used in organic Synthesis, pharmaceuticals, agrochemicals and dyestuff.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-8-9-4-6-12-7-5-9/h9,12H,4-8H2,1-3H3,(H,13,14)/p+1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7144-05-0 4-Aminomethylpiperidine 
• 172348-56-0 benzyl 4-(((tert-butoxycarbonyl)amino)methyl)piperidine-1-carboxylate 
• 1175526-48-3 3,5-dichlorobenzyl carbonochloridate 
• 173340-23-3 tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate 
• 88915-26-8 4-aminomethyl-1-benzylpiperidine 
• 375355-32-1 1-benzoylpiperidine-4-carboxamide 
• 39546-32-2 4-carboxamidopiperidine 
• 49761-82-2 tert-butyl 1H-imidazole-1-carboxylate 

Downstream Products

• 871022-23-0 tert-butyl [{1-(2-benzyloxycarbonyl-2-methylpropyl)piperidin-4-yl}methyl]carbamate 
• 871022-36-5 tert-butyl [{1-([1-(2-benzyltetrazol-5-yl)cyclopentyl]methyl)piperidin-4-yl}methyl]carbamate 
• 1260001-09-9 C₃₇H₅₁N₅O₅ 
• 1137475-21-8 5-(6-(4-(aminomethyl)piperidin-1-yl)pyrimidin-4-ylamino)pyrazine-2-carbonitrile 
• 1188915-36-7 tert-butyl 1-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-4-piperidinyl(methyl)carbamate 

Relevant articles and documents

The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity

The enzymatic activity of butyrylcholinesterase (BChE) in the brain increases with the progression of Alzheimer's disease, thus classifying BChE as a promising drug target in advanced Alzheimer's disease. We used structure-based drug discovery approaches to develop potent, selective, and reversible human BChE inhibitors. The most potent, compound 3, had a picomolar inhibition constant versus BChE due to strong cation-π interactions, as revealed by the solved crystal structure of its complex with human BChE. Additionally, compound 3 inhibits BChE ex vivo and is noncytotoxic. In vitro pharmacokinetic experiments show that compound 3 is highly protein bound, highly permeable, and metabolically stable. Finally, compound 3 crosses the blood-brain barrier, and it improves memory, cognitive functions, and learning abilities of mice in a scopolamine model of dementia. Compound 3 is thus a promising advanced lead compound for the development of drugs for alleviating symptoms of cholinergic hypofunction in patients with advanced Alzheimer's disease.

Autotaxin inhibitors

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.